Market Analysis
The global drug device combination market share is predicted
to grow at a whopping 7.2% CAGR over the assessment period 2023-2032.
Drug-device combination products relate a drug with that of a medical device to
bridge various regulatory frameworks (device or drug). This can be a single
product having several components such as drug-eluting stents, transdermal
patches or products that are separately packed yet intended for use exclusively
with a definite counterpart. Drug-device combination products offer an array of
advantages namely targeted drug delivery, improved patient compliance,
controlled drug administration and minimal side effects. Owing to its increased
sophistication and different advantages, drug device combination products are
widely adopted all across the medical sector.
There are
plentiful factors that is boosting the growth of the drug device combination market report. These factors as per the Market Research Future
(MRFR) report include increasing incidences of urology, prostate cancer,
diabetic neuropathy, colorectal cancer, respiratory problems and cardiovascular
diseases, growing healthcare expenditure, increasing awareness of market
products, growing geriatric population, technological advancements in the
drug-device combination product, increase in homebased healthcare market, high
market potential, and increase in healthcare expenditure. On the contrary, side
effects, existence of low-income countries, soaring price of products, strict
government rules for the approval of these devices and errors and
post-complications leading to various product recalls are factors that may
deter drug device combination market growth.
Key Players
Drug device combination market
players profiled in the industry include Zimmer Holding, Inc, Wright Medical
Group, Inc., Stryker Corporation, St. Jude Medical Inc, Smith & Nephew Plc,
Covidien Ltd, Cook Critical Care, Inc., C.R. BARD, Inc., Boston Scientific
Corporation, Biotronik, Biometrix Medical, Biomet Orthopedics, Inc, AlloSource,
Abbott Laboratories, 3M, and others.
Market Segmentation
MRFR
report provides an extensive segmental analysis of the drug device combination market on the basis of product,
application and end-users.
Based on
product, it is segmented into advanced wound care products, catheter and
others. Catheter is again segmented into wound drainage catheter,
thermodilution catheters, oximetry catheters, cardiovascular catheters,
urological catheters, antimicrobial catheter and others. Advanced wound care products
are again segmented into photodynamic therapy, drug eluting stents, antibiotic
bone cements, bone graft substitutes and antibiotic wound care. Bone graft
substitutes is again segmented into cell-based bone graft substitutes,
allograft-based bone graft substitutes, ceramic based bone graft substitute and
others.
Based on
application, the drug device combination market overview is segmented into
ophthalmic treatment, wound care, antimicrobial applications, bone treatment,
peripheral arterial disease, non-cardiovascular treatments, tachycardia
management, coronary angioplasty and others.
Based on end-users, it is segmented into academic and
research organization, ambulatory centers, hospitals and clinics and others.
Regional Analysis
By
region, the drug device combination market covers
growth opportunities and latest trends across the Americas, Europe, Asia
Pacific and Middle East and Africa. Of these, the Americas will sway the market
over the assessment period owing to increasing incidence of cardiovascular
diseases, presence of key market players, developed healthcare sector in Canada
and the US, high healthcare expenditure and suitable reimbursement policies. In
the European region, the drug device combination
market will have the second major share due to huge patient pool, presence of
developed economies, increasing awareness about the device and presence of
healthcare infrastructure that is well-developed. In the APAC region, the drug
device combination market is expected to grow at the fastest pace owing to
growing support from the government for foreign investments, growing healthcare
sector and growing penetration of market players here. On the other hand, the
drug device combination market in the Middle East and Africa will have minimal
share in the market owing to low per capita income and presence of poor
economies. The Middle East is anticipated to have a major share in the drug
device combination market owing to presence of developed economies such as
Dubai, Saudi Arabia, United Arab Emirates and others and increasing funds made
by the government in the healthcare sector.
About US:
Market Research Future (MRFR),
enable customers to unravel the complexity of various industries through Cooked
Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research
Reports (3R), Continuous-Feed Research (CFR), and Market Research &
Consulting Services.
Contact us:
Market Research Future (part of
Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor, New
York,
New York 10013
United States of America
No comments:
Post a Comment